Sangamo BioSciences | SGMO - Należności Handlowe





Należności Handlowe Zmiana Data
Alaunos Therapeutics USD 2K 0 2025-06
Alnylam Pharmaceuticals USD 883.96M 106.39M 2026-03
Alterity Therapeutics Limited AUD 4.57M 1.42M 2025-12
Amgen USD 9.14B 432M 2026-03
Bayer EUR 18.55B 4.36B 2026-03
BioCryst Pharmaceuticals USD 106.82M 15.49M 2025-12
Biogen USD 1.79B 76.6M 2026-03
BioMarin Pharmaceutical USD 903.91M 4.3M 2026-03
Cipla INR 62.19B 12.42B 2026-03
Clal Biotechnology ILS 3.75M 186K 2022-12
Compugen USD 2.34M 44K 2026-03
CSL USD 4.32B 1.35B 2025-12
Gilead Sciences USD 4.74B 172M 2026-03
GlaxoSmithKline GBP 7.94B 178M 2026-03
Grifols EUR 1B 285.88M 2025-12
Ionis Pharmaceuticals USD 74M 8M 2026-03
J&J USD 21.33B 3.72B 2025-12
Karyopharm Therapeutics USD 26.18M 5.6M 2025-12
Merck USD 11.78B 345M 2025-12
Novartis USD 9.6B 2.69B 2026-03
Omeros USD 8.08M 440K 2024-06
Pfizer USD 16.17B 332M 2026-03
Roche Holding CHF 11.9B 460M 2025-12
Sangamo BioSciences USD 581K 110K 2024-06
Sanofi EUR 482M 85M 2026-03
Sarepta Therapeutics USD 547.91M 149.68M 2026-03
Tectonic Therapeutic USD 0 270K 2023-12
Ultragenyx Pharmaceutical USD 60M 98M 2026-03
Vertex Pharmaceuticals USD 2B 56.7M 2026-03